Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B

NCT01298037 · View on ClinicalTrials.gov ↗

Study Summary

This is an ancillary to the NIDDK-sponsored Hepatitis B Research Network (HBRN) Study Cohort Study NCT01263587. This study will examine the balance between immune regulatory and effector responses in hepatitis B-infected participants enrolled in the HBRN study (NCT01263587).

Conditions Studied

Study Locations (12)

California

  • California Pacific Medical Center — San Francisco
  • University of California San Francisco Medical Center — San Francisco

Massachusetts

  • Massachusetts General Hospital — Boston
  • Beth Israel Deaconess Medical Center — Boston

Minnesota

  • University of Minnesota — Plymouth
  • Mayo Clinic Rochester — Rochester

Washington

  • Virginia Mason Medical Center — Seattle
  • Harborview Medical Center — Seattle

North Carolina

  • University of North Carolina — Chapel Hill

Texas

  • University of Texas Southwestern — Dallas

Virginia

  • Virginia Commonwealth University — Richmond

Ontario

  • University of Toronto — Toronto

Trial Details

FieldValue
Enrollment Target 201 participants
Start Date 2011-02-01
Est. Completion 2026-12-01

Sponsor

University of Pennsylvania

1,457 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01298037

The ClinicalTrials.gov registry entry for NCT01298037 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,457 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Hepatitis B appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01298037 reports 12 study locations spanning 8 distinct geographic areas — top geographies include California, Massachusetts, Minnesota. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01298037 about?

NCT01298037 is a clinical study titled "HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B". This is an ancillary to the NIDDK-sponsored Hepatitis B Research Network (HBRN) Study Cohort Study NCT01263587. This study will examine the balance between immune regulatory and effector responses in hepatitis B-infected participants enrolled in the HBRN study (NCT01263587).

What is the current status of trial NCT01298037?

This trial is currently active not recruiting. The enrollment target is 201 participants. The study started on 2011-02-01. Estimated completion is 2026-12-01.

What conditions does trial NCT01298037 study?

This clinical trial studies the following conditions: Hepatitis B. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT01298037?

This trial is sponsored by University of Pennsylvania, which has 1,457 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01298037 being conducted?

This trial has 12 study locations across California, Massachusetts, Minnesota, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial